Condition (MeSH)
Oral Submucous Fibrosis
ClinicalTrials.gov lists 14 trials for Oral Submucous Fibrosis or a narrower condition beneath it. Services Institute of Medical Sciences, Pakistan has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
14 of the 14 trials are tagged with Oral Submucous Fibrosis itself; the rest are tagged with a narrower condition beneath it.
When did Oral Submucous Fibrosis trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 2 |
| 2021 | 2 |
| 2018 | 1 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 2 |
| 2011 | 1 |
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Oral Submucous Fibrosis trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 2 |
| Phase 3 | 3 |
| Not applicable | 3 |
| Observational | 4 |
How many Oral Submucous Fibrosis trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 1 |
| Completed | 8 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Oral Submucous Fibrosis trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Services Institute of Medical Sciences, Pakistan | 1 |
Which drugs are being tested for Oral Submucous Fibrosis? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| CURCUMIN | 3 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Metformin | 2 |
| 10% Curcumin mucoadhesive gel | 1 |
| Hyaluronic acid 1% | 1 |
| [PRP] platelet rich plasma | 1 |
| Triamcinolone Acetonide alone | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Oral Submucous Fibrosis? (26)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Left colonic localization, non-granular morphology, and pit pattern independently predict submucosal fibrosis of naïve colorectal neoplasms before endoscopic submucosal dissection. | Surgical endoscopy | 2023 | Yes |
| Oral Submucous Fibrosis: Etiological Mechanism, Malignant Transformation, Therapeutic Approaches and Targets. | International journal of molecular sciences | 2023 | Yes |
| Drug treatment for oral submucous fibrosis: an update. | BMC oral health | 2023 | Yes |
| Black Turmeric and Aloe Vera in the Management of Oral Submucous Fibrosis: A Prospective Clinical Study. | Asian Pacific journal of cancer prevention : APJCP | 2021 | Yes |
| Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments. | International journal of molecular sciences | 2020 | Yes |
Showing 5 of 26 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Oral submucous fibrosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Oral submucous fibrosis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Oral submucous fibrosis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Oral submucous fibrosis | 357154 | Exact | Orphadata Science knowledge files, Product 1 |
| Oral submucous fibrosis | 357154 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.